该研究数据在2024年美国临床肿瘤学会（ASCO）年会上公布，结果显示：中位随访约3年（34.9个月），与单独使用帕博利珠单抗相比，复发或死亡风险降低了49%，远处转移或死亡的风险降低了62%。mRNA-4157（V940）联合帕博利珠单抗的2.5年无复发生存率为74.8%，而单独使用帕博利珠单抗的2.5年无复发生存率为55.6%。...
3. mRNA Technology: What It Is and How It Works (http://pfizer.com) 4. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial | Nature Medicine 5. Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Per...
在完全切除后复发风险较高的黑色素瘤患者中,mRNA-4157(V940)和pembro在RFS方面的临床显著改善,与标准治疗pembro单药相比,经过2年的随访,复发或死亡的风险降低了44%; 与单独使用pembrolizumab相比,mRNA-4157(V940)与pembro联合使用耐受性良好,没有增加3-4级irAE或严重AE mRNA-4157(V940)与pembrolizumab联合用药于202...
3. mRNA Technology: What It Is and How It Works (pfizer.com) 4. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial | Nature Medicine 5. Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence ...
Zaks T. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024 Jan 18:S0140-6736(23)02268-7. doi: 10.1016/S0140-6736(23)02268-7IF: 168.9 Q1 . Epub ahead of print...
https://www.onclive.com/view/mrna-4157-plus-pembrolizumab-under-further-investigation-in-phase-3-trial-in-high-risk-melanoma 本网站新闻资讯、文章、研究数据、治疗案例均来自于国内外医学论文,所涉及到的新药、新技术有可能还处于临床研究阶段,患者不能作为治疗疾病的依据。癌症治疗目前尚无治愈手段,患者需要在...
The combination of mRNA-4157 and pembrolizumab will be further evaluated as an adjuvant treatment option for patients with resected, high-risk, stage IIB to IV melanoma in the phase 3 V940-001 trial.
The phase 3 INTerpath-002 study design: Individualized neoantigen therapy (INT) V940 (mRNA-4157) plus pembrolizumab vs placebo plus pembrolizumab for resected early-stage non–small-cell lung cancer (NSCLC).doi:10.1200/JCO.2024.42.16_suppl.TPS8116...
1.https://.businesswire/news/home/20190601005011/en/Moderna%C2% A0Announces-Presentation-Interim-Data-Phase-1-Study 2.https://.modernatx/pipeline/therapeutic-areas/immuno-oncology 3.http://abstracts.asco/239/AbstView_239_263681.html 4. http://abstracts.asco/239/AbstView_239_268519.html...
INTerpath-001 (NCT05933577): a randomized phase 3 trial evaluating mRNA-4157 plus pembrolizumab as an adjuvant treatment in patients with resected high-risk (stages IIB through IV) melanoma, which is actively enrolling INTerpath-002 (NCT06077760): a randomized phase 3 ...